Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Next Previous
Trial Profile

Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms REFINE-ALS
  • Sponsors Mitsubishi Tanabe Pharma America

Most Recent Events

  • 05 Jun 2024 According to a Mitsubishi Tanabe Pharma America media release, Interim analysis of Radicava/Edaravone findings in Biomarkers from this trial to be included in a presentation at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 Annual Meeting being held in Stockholm, Sweden from June 17-20, 2024.
  • 01 Mar 2024 According to a Mitsubishi Tanabe Pharma America media release, the company will share findings from our ongoing Phase 4 REFINE-ALS biomarker study and results from multiple real-word studies in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
  • 05 Dec 2023 According to a Mitsubishi Tanabe Pharma America media release, interim results of this study will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top